miRNA therapeutics in cardiovascular diseases: promises and problems

被引:77
|
作者
Nouraee, Nazila [1 ]
Mowla, Seyed J. [1 ]
机构
[1] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
来源
FRONTIERS IN GENETICS | 2015年 / 6卷
关键词
ACUTE MYOCARDIAL-INFARCTION; CIRCULATING MICRORNAS; ATRIAL-FIBRILLATION; CARDIAC FIBROSIS; HEART-FAILURE; EXOSOMES; BIOMARKER; BIOGENESIS; DIAGNOSIS; CANCER;
D O I
10.3389/fgene.2015.00232
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
microRNAs (miRNAs) are a novel class of non-coding RNAs which found their way into the clinic due to their fundamental roles in cellular processes such as differentiation, proliferation, and apoptosis. Recently, miRNAs have been known as micromodulators in cellular communications being involved in cell signaling and microenvironment remodeling. In this review, we will focus on the role of miRNAs in cardiovascular diseases (CVDs) and their reliability as diagnostic and therapeutic biomarkers in these conditions. CVDs comprise a variety of blood vessels and heart disorders with a high rate of morbidity and mortality worldwide. This necessitates introduction of novel molecular biomarkers for early detection, prevention, or treatment of these diseases. miRNAs, due to their stability, tissue-specific expression pattern and secretion to the corresponding body fluids, are attractive targets for cardiovascular-associated therapeutics. Explaining the challenges ahead of miRNA-based therapies, we will discuss the exosomes as delivery packages for miRNA drugs and promising novel strategies for the future of miRNA-based therapeutics. These approaches provide insights to the future of personalized medicine for the treatment of CVDs.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] siRNA, miRNA and HIV: promises and challenges
    Yeung, ML
    Bennasser, Y
    Le, SY
    Jeang, KT
    CELL RESEARCH, 2005, 15 (11-12) : 935 - 946
  • [42] It is Time to Revisit miRNA Therapeutics
    Corey, David R.
    NUCLEIC ACID THERAPEUTICS, 2025, 35 (01) : 1 - 5
  • [43] Digesting dietary miRNA therapeutics
    Yarmarkovich, Mark
    Hirschi, Kendal D.
    ONCOTARGET, 2015, 6 (16) : 13848 - 13849
  • [44] MiRNA therapeutics heading to the clinic
    Razvi, Enal
    Genetic Engineering and Biotechnology News, 2014, 34 (03):
  • [45] Emerging role of sphingolipids and extracellular vesicles in development and therapeutics of cardiovascular diseases
    Bhat, Owais Mohmad
    Mir, Rakeeb Ahmad
    Nehvi, Iqra Bashir
    Wani, Nissar Ahmad
    Dar, Abid Hamid
    Zargar, M. Afzal
    IJC HEART & VASCULATURE, 2024, 53
  • [46] Novel Therapeutics and Upcoming Clinical Trials Targeting Inflammation in Cardiovascular Diseases
    Potere, Nicola
    Bonaventura, Aldo
    Abbate, Antonio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44 (12) : 2371 - 2395
  • [47] Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
    Corbic, Milena
    Sretenovic, Jasmina
    Zivkovic, Vladimir
    Jakovljevic, Vladimir
    Turnic, Tamara Nikolic
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2023, 52 (05) : 870 - 879
  • [48] Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases
    Qin, Yanwen
    Shi, Guo-Ping
    PHARMACOLOGY & THERAPEUTICS, 2011, 131 (03) : 338 - 350
  • [49] Multiomics Network Medicine Approaches to Precision Medicine and Therapeutics in Cardiovascular Diseases
    Wang, Rui-Sheng
    Maron, Bradley A.
    Loscalzo, Joseph
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43 (04) : 493 - 503
  • [50] Role and mechanism of miRNA in cardiac microvascular endothelial cells in cardiovascular diseases
    Yan, Junyuan
    Zhong, Xinqin
    Zhao, Yucui
    Wang, Xiaoying
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11